#levodopa market outlook
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
Tumblr’s reach among the 26-to-35-year-olds in the US is 11%.
Text
Levodopa Market: Key Trends and Developments in Parkinson’s Disease Treatment up to 2033
Market Definition The Levodopa Market centers around the production and distribution of levodopa, a critical medication used primarily for the treatment of Parkinson’s disease and dopamine-responsive dystonia. As the gold-standard treatment for Parkinson’s disease, levodopa works by converting to dopamine in the brain, replenishing the neurotransmitter that becomes deficient in patients suffering from this degenerative neurological disorder. Available in various formulations, including oral tablets, capsules, and combination drugs (such as carbidopa-levodopa), levodopa remains a vital therapeutic option.
To Know More @ https://www.globalinsightservices.com/reports/levodopa-market
The global Levodopa market is anticipated to expand from $4.2 billion in 2023 to $7.5 billion by 2033, reflecting a compound annual growth rate (CAGR) of 5.8%.
Market Outlook The Levodopa Market is poised for steady growth, driven by the increasing prevalence of Parkinson’s disease worldwide and the ongoing demand for effective treatments. The aging global population is a significant factor contributing to the rising incidence of Parkinson’s, as the disease is more common among older adults. As awareness of neurological disorders improves and diagnostic capabilities advance, more patients are being identified, further boosting the demand for levodopa-based therapies.
A key trend in the market is the development of new formulations and delivery methods aimed at enhancing the efficacy and patient adherence of levodopa treatment. Continuous research is underway to optimize the absorption and bioavailability of levodopa, as well as to reduce its side effects, such as motor fluctuations and dyskinesia. Innovative delivery systems, such as intestinal gel formulations and extended-release capsules, are being explored to provide more consistent symptom control.
Pharmaceutical companies are also investing in combination therapies that incorporate levodopa with other drugs to improve therapeutic outcomes. For example, adding enzyme inhibitors like entacapone or carbidopa helps to prevent the breakdown of levodopa before it reaches the brain, enhancing its effectiveness and reducing the required dosage. These advancements are crucial in improving the quality of life for Parkinson’s patients, who often experience a decline in treatment efficacy over time.
However, the market faces challenges related to the side effects and long-term complications of levodopa therapy. The development of motor complications, such as dyskinesia and the “on-off” phenomenon, remains a concern, prompting ongoing research into alternative treatment strategies and adjunctive therapies. Additionally, the high cost of advanced levodopa formulations can be a barrier for patients in low- and middle-income countries, where access to quality healthcare remains limited.
Request the sample copy of report @ https://www.globalinsightservices.com/request-sample/GIS32379
Research Objectives
Estimates and forecast the overall market size for the total market, across product, service type, type, end-user, and region
Detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling
Identify factors influencing market growth and challenges, opportunities, drivers and restraints
Identify factors that could limit company participation in identified international markets to help properly calibrate market share expectations and growth rates
Trace and evaluate key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities
Thoroughly analyze smaller market segments strategically, focusing on their potential, individual patterns of growth, and impact on the overall market
To thoroughly outline the competitive landscape within the market, including an assessment of business and corporate strategies, aimed at monitoring and dissecting competitive advancements.
Identify the primary market participants, based on their business objectives, regional footprint, product offerings, and strategic initiatives
Request For Report Customization @ https://www.globalinsightservices.com/request-customization/GIS32379
Market Segmentation
In 2023, the Levodopa market volume was estimated at 320 million units, with projections to reach 500 million units by 2033. The oral administration segment dominates the market, holding a 55% share, while the injectable segment follows with 30%. The transdermal segment, although smaller at 15%, is experiencing rapid growth due to advancements in drug delivery systems. The demand for Levodopa is primarily driven by its effectiveness in managing Parkinson’s disease symptoms, with North America and Europe being the largest consumers due to high prevalence rates and advanced healthcare infrastructure.
Competitive dynamics are heavily influenced by key players such as AbbVie Inc., Merck & Co., and Teva Pharmaceutical Industries. These companies leverage strategic collaborations and R&D investments to maintain market leadership. Regulatory frameworks, particularly those by the FDA and EMA, significantly impact market strategies, focusing on drug safety and efficacy. Future projections indicate a 10% annual growth rate, driven by an aging population and increased awareness of neurological disorders. However, stringent regulations and high R&D costs remain challenges. The integration of AI in drug development and personalized medicine approaches is expected to offer new growth opportunities in the Levodopa market.
Major Players
Mylan
Teva Pharmaceutical Industries
Sun Pharmaceutical Industries
Cipla
Zydus Cadila
Aurobindo Pharma
Torrent Pharmaceuticals
Alkem Laboratories
Lupin Pharmaceuticals
Dr Reddy’s Laboratories
Wockhardt
Intas Pharmaceuticals
Glenmark Pharmaceuticals
Hikma Pharmaceuticals
Apotex
Amneal Pharmaceuticals
Endo International
Perrigo Company
Mallinckrodt Pharmaceuticals
Lannett Company
Request For Discounted Pricing @ https://www.globalinsightservices.com/request-special-pricing/GIS32379
Research Scope
Scope – Highlights, Trends, Insights. Attractiveness, Forecast
Market Sizing – Product Type, End User, Offering Type, Technology, Region, Country, Others
Market Dynamics – Market Segmentation, Demand and Supply, Bargaining Power of Buyers and Sellers, Drivers, Restraints, Opportunities, Threat Analysis, Impact Analysis, Porters 5 Forces, Ansoff Analysis, Supply Chain
Business Framework – Case Studies, Regulatory Landscape, Pricing, Policies and Regulations, New Product Launches. M&As, Recent Developments
Competitive Landscape – Market Share Analysis, Market Leaders, Emerging Players, Vendor Benchmarking, Developmental Strategy Benchmarking, PESTLE Analysis, Value Chain Analysis
Company Profiles – Overview, Business Segments, Business Performance, Product Offering, Key Developmental Strategies, SWOT Analysis
For In-Depth Competitive Analysis, Buy Now @ https://www.globalinsightservices.com/checkout/single_user/GIS32379
About Us
With Global Insight Services, you receive:
10-year forecast to help you make strategic decisions
In-depth segmentation which can be customized as per your requirements
Free consultation with lead analyst of the report
Infographic excel data pack, easy to analyze big data
Robust and transparent research methodology
Unmatched data quality and after sales service
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
0 notes
Text
Levodopa Market - Size, Share, Outlook, and Analysis by 2018-2026
Development of novel formulations and efficient drug delivery methods for levodopa are expected to drive growth of the levodopa market. For instance, a clinical study for gastric retentive Accordion Pill, an immediate drug release formulation by Intec Pharma Ltd., is ongoing in clinical phase III and is expected to complete in September 2018. Accordion Pill is a Carbidopa/Levodopa (AP-CD/LD) combinational oral drug delivery system, which is designed to improve the efficacy and safety of existing CD/LD drugs by utilizing an efficient gastric retention and specific release mechanism.
Moreover, Impel NeuroPharma Inc. is conducting phase II clinical study for INP103, a drug-device combination product containing a drug component, L-dopa, and device component I231 Precision Olfactory Delivery (POD) device. The study is expected to complete in November 2018.
Get Request sample copy for Industry Insight: https://www.coherentmarketinsights.com/insight/request-sample/2247
Furthermore, advancement in diagnosis of Parkinson's disease (PD) progression is expected to boost growth of levodopa market. For instance, a clinical study conducted by Washington University School of Medicine, for measuring PD progression both by using Magnetic Resonance Imaging (MRI) and by controlled dose of levodopa for discovering suitable biomarker of PD is currently in clinical phase I and is expected to complete in February 2019.
Shortage of drug supply in the market due to delay in manufacturing and supply of levodopa is expected to hamper levodopa market growth. For instance, Merck Sharp & Dohme Ireland (Human Health) Ltd. in September 2018, anticipated stock shortage of some Sinemet (Carbidopa/ Levodopa) products in the Irish market in near future due to global manufacturing delays in production and demand for resupply of these products.
North America is expected to dominate the global levodopa market, owing to approval of new products by the U.S. Food and Drug Administration (FDA). For instance, in 2015, FDA approved an extended-release oral formulation of Levodopa/Carbidopa called Duopa, manufactured by AbbVie Inc., in the U.S. market. Duopa is a gel formulation of Carbidopa/Levodopa enteral suspension and is administered using a small, portable infusion pump that delivers Carbidopa and Levodopa directly into the small intestine, which continuously release over 16 hours in the body.
Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2247
Europe region is expected to witness significant growth in levodopa market due to involvement of key players for marketing novel formulations in European region. For instance, Acorda Therapeutics, Inc., in March 2018, submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for INBRIJA, an investigational inhaled levodopa treatment for symptoms of OFF periods (OFF symptoms implies recurrence of symptoms such as rigidity, and tremors after long period of levodopa use) in people with PD taking a Carbidopa/Levodopa regimen.
The key players operating in levodopa market include, Taj Pharmaceuticals Limited., Guangzhou HanFang Pharmaceutical Company Limited, Poulvet.com, Teva Pharmaceutical Industries Ltd., UBM, Zhejiang Wild Wind Pharmaceutical Co., Ltd., and SWAPNROOP.
0 notes
Text
Levodopa Market Positive Long-Term Growth Outlook 2018-2026
Levodopa or L-Dopa is a chemical building-block that converts into a dopamine in body. Dopamine is the chemical messenger released in brain. It mediates pleasure, cognition, and memory functions. Nearly all patients receive the dopamine precursor levodopa, which adequately control symptoms of Parkinson's disease (PD) at early stage of the disease. Carbidopa is often included with levodopa-containing drugs in order to boost its efficacy by slowing down the metabolism of dopamine. Click To Read More On Levodopa Market
Levodopa Market Driver
Development of novel formulations and efficient drug delivery methods for levodopa are expected to drive growth of the levodopa market. For instance, a clinical study for gastric retentive Accordion Pill, an immediate drug release formulation by Intec Pharma Ltd., is ongoing in clinical phase III and is expected to complete in September 2018. Accordion Pill is a Carbidopa/Levodopa (AP-CD/LD) combinational oral drug delivery system, which is designed to improve the efficacy and safety of existing CD/LD drugs by utilizing an efficient gastric retention and specific release mechanism.
Moreover, Impel NeuroPharma Inc. is conducting phase II clinical study for INP103, a drug-device combination product containing a drug component, L-dopa, and device component I231 Precision Olfactory Delivery (POD) device. The study is expected to complete in November 2018.
Furthermore, advancement in diagnosis of Parkinson's disease (PD) progression is expected to boost growth of levodopa market. For instance, a clinical study conducted by Washington University School of Medicine, for measuring PD progression both by using Magnetic Resonance Imaging (MRI) and by controlled dose of levodopa for discovering suitable biomarker of PD is currently in clinical phase I and is expected to complete in February 2019.
Levodopa Market Restraint
Shortage of drug supply in the market due to delay in manufacturing and supply of levodopa is expected to hamper levodopa market growth. For instance, Merck Sharp & Dohme Ireland (Human Health) Ltd. in September 2018, anticipated stock shortage of some Sinemet (Carbidopa/ Levodopa) products in the Irish market in near future due to global manufacturing delays in production and demand for resupply of these products.
Competitive Landscape
The key players operating in levodopa market include, Taj Pharmaceuticals Limited., Guangzhou HanFang Pharmaceutical Company Limited, Poulvet.com, Teva Pharmaceutical Industries Ltd., UBM, Zhejiang Wild Wind Pharmaceutical Co., Ltd., and SWAPNROOP.
Levodopa Market – Regional Analysis
On the basis of region, the global levodopa market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to dominate the global levodopa market, owing to approval of new products by the U.S. Food and Drug Administration (FDA). For instance, in 2015, FDA approved an extended-release oral formulation of Levodopa/Carbidopa called Duopa, manufactured by AbbVie Inc., in the U.S. market. Duopa is a gel formulation of Carbidopa/Levodopa enteral suspension and is administered using a small, portable infusion pump that delivers Carbidopa and Levodopa directly into the small intestine, which continuously release over 16 hours in the body.
Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2247
Europe region is expected to witness significant growth in levodopa market due to involvement of key players for marketing novel formulations in European region. For instance, Acorda Therapeutics, Inc., in March 2018, submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for INBRIJA, an investigational inhaled levodopa treatment for symptoms of OFF periods (OFF symptoms implies recurrence of symptoms such as rigidity, and tremors after long period of levodopa use) in people with PD taking a Carbidopa/Levodopa regimen.
Furthermore, in November 2015, Impax Laboratories, Inc. received European Commission (EC) marketing authorization for NUMIENT (Levodopa and Carbidopa), a modified-release oral capsule formulation for the symptomatic treatment of adult patients with Parkinson's disease in Europe region.
Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at [email protected]
https://www.coherentmarketinsights.com/phase-xs/
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]
0 notes
Text
Global Anti-Parkinson Drugs Market Competitive Strategies and Forecasts to 2031
The Anti-Parkinson Drugs Global Market Report 2021-31 by The Business Research Company describes and explains the global anti-Parkinson drugs market and covers 2016 to 2021, termed the historic period, and 2022 to 2026, termed the forecast period, along with further forecasts for the period 2026-2031. The report evaluates the market across each region and for the major economies within each region.
The Anti-Parkinson Drugs Global Market Report 2022 covers anti-Parkinson drugs market drivers, anti-Parkinson drugs market trends, anti-Parkinson drugs market segments, anti-Parkinson drugs market growth rate, anti-Parkinson drugs market major players, and anti-Parkinson drugs market size.
View Complete Report:
The anti-Parkinson drugs market report provides in-depth analysis of the impact of COVID-19 on the global anti-Parkinson drugs industry along with revised market numbers due to the effects of the coronavirus and the expected anti-Parkinson drugs market growth numbers for 2022-2031.
The global anti-Parkinson’s drugs market size is expected to grow from $8.86 billion in 2021 to $9.56 billion in 2022 at a compound annual growth rate (CAGR) of 7.9%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global anti-Parkinson drugs market share is expected to reach $12.25 billion in 2026 at a CAGR of 6.4%.
Request Report Sample Now: https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp
Anti-Parkinson Drugs Global Market Report 2022 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The chapter on the impact of COVID-19 gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market. The chapter also covers markets which have been positively affected by the pandemic.
TBRC’s report covers the anti-Parkinson drugs market segments- 1) By Drugs Class: Levodopa/Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Others
2) By Route of Administration: Oral, Injection, Transdermal
3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies
Table Of Contents
1. Executive Summary
2. Anti-Parkinson Drugs Market Characteristics
3. Anti-Parkinson Drugs Market Trends And Strategies
4. Impact Of COVID-19 On Anti-Parkinson Drugs
5. Anti-Parkinson Drugs Market Size And Growth
.
.
27. Anti-Parkinson Drugs Market Competitive Landscape And Company Profiles
28. Anti-Parkinson Drugs Pipeline Analysis
29. Key Mergers And Acquisitions In The Anti-Parkinson Drugs Market
30. Anti-Parkinson Drugs Market Future Outlook and Potential Analysis
31. Appendix
About The Business Research Company: The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology. It has offices in the UK, the US and India and a network of trained researchers in 20+ countries globally.
Contact Information: The Business Research Company Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Find us on
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany/
Blog: http://blog.tbrc.info/
#market research#marketstrategy#markettrends#tbrc#thebusinessresearchcompany#marketreport#marketresearch#business
0 notes
Text
Levodopa Market Size, Share, Outlook, and Opportunity Analysis, 2019– 2027
Levodopa Market by Application (Parkinson’s disease and Dopamine Responsive Dystonia), by Drug Type (Rytary, Duopa, Sinemet, Canamet, and Others), by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis 2018 – 2026.
Levodopa or L-Dopa is a chemical building-block that converts into a dopamine in body. Dopamine is the chemical messenger released in brain. It mediates pleasure, cognition, and memory functions. Nearly all patients receive the dopamine precursor levodopa, which adequately control symptoms of Parkinson's disease (PD) at early stage of the disease. Carbidopa is often included with levodopa-containing drugs in order to boost its efficacy by slowing down the metabolism of dopamine.
Levodopa Market Driver
Development of novel formulations and efficient drug delivery methods for levodopa are expected to drive growth of the levodopa market. For instance, a clinical study for gastric retentive Accordion Pill, an immediate drug release formulation by Intec Pharma Ltd., is ongoing in clinical phase III and is expected to complete in September 2018. Accordion Pill is a Carbidopa/Levodopa (AP-CD/LD) combinational oral drug delivery system, which is designed to improve the efficacy and safety of existing CD/LD drugs by utilizing an efficient gastric retention and specific release mechanism.
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2247
Moreover, Impel NeuroPharma Inc. is conducting phase II clinical study for INP103, a drug-device combination product containing a drug component, L-dopa, and device component I231 Precision Olfactory Delivery (POD) device. The study is expected to complete in November 2018.
Furthermore, advancement in diagnosis of Parkinson's disease (PD) progression is expected to boost growth of levodopa market. For instance, a clinical study conducted by Washington University School of Medicine, for measuring PD progression both by using Magnetic Resonance Imaging (MRI) and by controlled dose of levodopa for discovering suitable biomarker of PD is currently in clinical phase I and is expected to complete in February 2019.
Levodopa Market Restraint
Shortage of drug supply in the market due to delay in manufacturing and supply of levodopa is expected to hamper levodopa market growth. For instance, Merck Sharp & Dohme Ireland (Human Health) Ltd. in September 2018, anticipated stock shortage of some Sinemet (Carbidopa/ Levodopa) products in the Irish market in near future due to global manufacturing delays in production and demand for resupply of these products.
Levodopa Market – Regional Analysis
On the basis of region, the global levodopa market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/levodopa-market-2247
North America is expected to dominate the global levodopa market, owing to approval of new products by the U.S. Food and Drug Administration (FDA). For instance, in 2015, FDA approved an extended-release oral formulation of Levodopa/Carbidopa called Duopa, manufactured by AbbVie Inc., in the U.S. market. Duopa is a gel formulation of Carbidopa/Levodopa enteral suspension and is administered using a small, portable infusion pump that delivers Carbidopa and Levodopa directly into the small intestine, which continuously release over 16 hours in the body.
Europe region is expected to witness significant growth in levodopa market due to involvement of key players for marketing novel formulations in European region. For instance, Acorda Therapeutics, Inc., in March 2018, submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for INBRIJA, an investigational inhaled levodopa treatment for symptoms of OFF periods (OFF symptoms implies recurrence of symptoms such as rigidity, and tremors after long period of levodopa use) in people with PD taking a Carbidopa/Levodopa regimen.
Furthermore, in November 2015, Impax Laboratories, Inc. received European Commission (EC) marketing authorization for NUMIENT (Levodopa and Carbidopa), a modified-release oral capsule formulation for the symptomatic treatment of adult patients with Parkinson's disease in Europe region.
The key players operating in levodopa market include, Taj Pharmaceuticals Limited., Guangzhou HanFang Pharmaceutical Company Limited, Poulvet.com, Teva Pharmaceutical Industries Ltd., UBM, Zhejiang Wild Wind Pharmaceutical Co., Ltd., and SWAPNROOP.
Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2247
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
0 notes
Text
Parkinson’s disease therapeutics market 2021 to 2027, key industry players & growth trends
According to a Global Market Insights, Inc., analysis report, global Parkinson’s disease therapeutics market size is projected to surpass US$8 billion by 2027. The Parkinson’s Disease Biomarkers Program (PDBP) funding endorse discovery projects to encourage the identification of developments and diagnostic biomarkers for the disease. Consequently, a substantial rise in funding towards R&D programs for the development of novel therapies will propel the demand for Parkinson’s therapeutics in the forthcoming years.
The Parkinson’s disease therapeutics market expansion would be augmented by extensive investments in R&D activities to uplift the development in the treatment of the disease. Reportedly, the Parkinson’s Foundation in 2020 invested nearly US$3.5 million in 34 research programs to support the efforts of promising scientists in the field of Parkinson’s disease (PD).
Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/2724
The Parkinson’s disease therapeutics industry progression would further be augmented by the growing awareness among the population about the disease. Early diagnosis of the disease plays a key role in providing effective treatment to the affected patient. The lack of awareness and knowledge among people about Parkinson’s disease has led to the commencement of numerous awareness programs. For instance, World Parkinson’s Day is an initiative to encourage new research and treatment programs by creating awareness among the population pertaining to the disease.
The dopamine agonists segment accounted for a considerable revenue share at nearly US$694 million in 2020. The medication is highly preferred in the treatment of Parkinson’s disease owing to its resemblance to the effect of dopamine in the brain. The medication does not contain any side effects such as dyskinesia, which is mostly caused by other drugs. These drugs are adopted to improve the condition-related symptoms by indicating the presence of dopamine in the brain, therefore propelling industry growth.
The adult patient segment of the Parkinson’s disease therapeutics industry is expected to grow at 6.9% CAGR up to 2027. The segment expansion is majorly attributed to the growing vulnerability to idiopathic Parkinson’s disease among the aging population base. The rapidly growing aging population base across the globe has resulted in a large number of patients being affected by Parkinson’s disease.
The Brazil Parkinson’s disease therapeutics industry was over US$90 million in 2020. The regional industry progression is predominantly driven by robust economic expansion, substantial development in healthcare infrastructure, and rising incidences of Parkinson’s disease in the country. Also, the presence of dynamic pharmacology and biotechnology research sector backed by the Brazilian government will provide exponential growth opportunities to the regional industry.
Leading firms functioning in the Parkinson’s disease therapeutics industry include Teva Pharmaceutical, Acadia Pharmaceuticals, AbbVie Inc., UCB, Amneal Pharmaceuticals, Roche, and Orion Corporation, among others.
Request for a Customization of this research report @ https://www.gminsights.com/roc/2724
Browse key industry insights spread across 150 pages with 180 market data tables & 15 figures & charts from the report, “Parkinson’s Disease Therapeutic Market Size By Drug Class (Levodopa/Carbidopa, Dopamine Agonists, Adenosine A2A Antagonist, COMT Inhibitors, MAO-B Inhibitors, Glutamate Antagonist), By Route of Administration (Oral, Subcutaneous, Transdermal), By Patient (Adult, Pediatric), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2021 – 2027” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/parkinsons-disease-therapeutics-market
About Global Market Insights:
Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.
Contact Us:
Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone:1-302-846-7766
Toll Free: 1-888-689-0688
Email: [email protected]
Web: https://www.gminsights.com/
0 notes
Text
Dopamine Agonist Drug Market In-Depth Analysis Globally by Top Key Players-, Intas Pharmaceuticals Ltd.
Dopamine Agonist Drug Market Dopamine agonists are the class of drugs that stimulates postsynaptic dopamine receptors directly in the brain. It is most widely used to treat the symptoms of Parkinson’s disease (PD). It works by reducing the motor fluctuations in person with Parkinson’s disease.
Market Drivers
Ongoing clinical trial conducted by many pharmaceuticals industries is propelling the growth of this market
Increase in special designation from the regulatory authorities is boosting the market growth
High demand of disease specific novel treatment can also act as a market driver
The competitive scenario of market and strategic collaborations may boost the market position
Market Restraints
Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this market
Low healthcare budget in some developing countries is hamper the market growth
Patent expiration of branded drugs and introduction of generics is also hinders the market growth
Get Exclusive Sample Report: @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-dopamine-agonist-drug-market
Scope of the Dopamine Agonist Drug Market
Current and future of Dopamine Agonist Drug Market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
Regions/Countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players
Global Dopamine Agonist Drug Market By Type (Non-Ergoline Dopamine Agonists, Ergot-Derived Dopamine Agonists), Recombinant Factor VIII and Others), Indication (Parkinson's Disease, Restless Leg Syndrome and Others), Drugs (Carbidopa and Levodopa, Ropinirole, Pramipexole, Cabergoline, Bromocriptine and Others), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2026
Browse Related Report Here:
North America Psychedelic Drugs Market
U.S. Warts Treatment Market
Some of the leading key players profiled in this study:
Few of the major competitors currently working in the global dopamine agonist drug market are GlaxoSmithKline plc, Intas Pharmaceuticals Ltd, Amarin Corporation, Acorda Therapeutics, Inc, US WorldMeds, LLC, Kirin Holdings Company, Limited, UCB S.A., Bausch Health, Boehringer Ingelheim International GmbH, Intec Pharma Ltd, Merck & Co., Inc, Novartis AG, Serina Therapeutics, Apotex Inc, Teva Pharmaceutical Industries Ltd, Mylan N.V., Glenmark Pharmaceuticals Ltd, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories Ltd, Intec Pharma Ltd and others.
Get Detailed Toc and Charts & Tables @ https://www.databridgemarketresearch.com/toc/?dbmr=global-dopamine-agonist-drug-market
Key Pointers Covered in the Dopamine Agonist Drug Market Trends and Forecast to 2026
Dopamine Agonist Drug Market New Sales Volumes
Dopamine Agonist Drug Market Replacement Sales Volumes
Dopamine Agonist Drug Market Installed Base
Dopamine Agonist Drug Market By Brands
Dopamine Agonist Drug Market Size
Dopamine Agonist Drug Market Procedure Volumes
Dopamine Agonist Drug Market Product Price Analysis
Dopamine Agonist Drug Market Healthcare Outcomes
Dopamine Agonist Drug Market Cost of Care Analysis
Dopamine Agonist Drug Market Regulatory Framework and Changes
Dopamine Agonist Drug Market Prices and Reimbursement Analysis
Dopamine Agonist Drug Market Shares in Different Regions
Recent Developments for Dopamine Agonist Drug Market Competitors
Dopamine Agonist Drug Market Upcoming Applications
Dopamine Agonist Drug Market Innovators Study
Inquiry before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-dopamine-agonist-drug-market
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]
#Dopamine Agonist Drug Market#Dopamine Agonist Drug Market report#Dopamine Agonist Drug Market research
0 notes
Text
Nasal Drug Delivery Systems Market - Global Forecast to 2026
Nasal cavity is becoming one of the most potential and promising route of drug delivery, owing to its advantages such as bypassing the hepatic first-pass metabolism, and most importantly patient convenience. The report provides in depth understanding of developing intranasal formulation to achieve better therapeutic objective, in turn drive the market share.
However, the report also focuses on the practical and technical factors which remains the hindrance for the global nasal drug delivery system market growth over the forecast period. Furthermore, report tracks and forecast the market growth of each segment for the period of 2016-2026.
Request A Sample Copy: http://bit.ly/321QbG3
Market Dynamics
The major factors driving growth of the nasal drug delivery systems market includes, increasing product launches coupled with technologically advanced drug delivery systems and increasing incidence of nasal cavity associated diseases. For instance, in June 2018, Insys Therapeutics, Inc., a specialty pharmaceutical company, conducted clinical trial for epinephrine nasal spray, an alternative for intramuscular injection for the indication of anaphylaxis.
Furthermore, companies have large number of pipeline drugs, which are to be delivered intranasally such as Acerus Pharmaceuticals Corporation is investigating TEFINA, a testosterone nasal gel, for addressing the unmet treatment demand for female sexual dysfunction. However, intranasal route of drug delivery is not suitable for all drug types, which is expected to be a major restrain for growth of the nasal drug delivery systems market.
Increasing awareness about advantages of nasal drug delivery is driving the nasal drug delivery systems market growth
Major advantages of nasal drug delivery is that, the drug circumvents hepatic first-pass metabolism, leading to high bioavailability as compared to drug administered orally. On the other hand, parenteral route of administration is also inconvenient for long term therapeutic treatment.
Nasal cavity being highly vascular enhances the drug absorption resulting in rapid onset of action. Moreover, ease of administration coupled with non-invasive method is driving adoption of nasal drug delivery systems, in turn propelling nasal drug delivery systems market growth.
However, limitations associated with nasal drug delivery system such as histological toxicity or lesser area of absorption as compared to orally administered drug hinders the nasal drug delivery systems market growth.
Furthermore, increasing product launches with nasal drug delivery is also fueling the nasal drug delivery systems market growth. For instance, in 2017, Optinose, an ENT / Allergy specialty pharmaceutical company, received New Drug Application approval for its Xhance, fluticasone propionate, for the indication of nasal polyps in adults. Xhance is a specially designed combination of novel Optinose Exhalation Delivery System and an aqueous suspension of microfine drug delivery for topical intranasal administration via a metered atomizing spray pump. Moreover, the product can be opted for powder and liquid formulation and also addresses the limitation of traditional nasal spray by using its bi-directional delivery.
Nasal drug delivery systems market regional outlook - Asia Pacific is expected to be a rapidly growing market over the forecast period
The regional nasal drug delivery systems market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa by Coherent Market Insights. North America nasal drug delivery systems market is estimated to hold dominant position in 2017. The factors attributed to growth of the North America in nasal drug delivery systems market is increasing research and development by local manufacturers to develop new drug device or delivery system combination.
For instance, Impel NeuroPharma, Inc., a Seattle-based clinical stage biotechnology company, is engaged in applying its Precision Olfactory Delivery (POD) nasal drug delivery platform for drugs such as levodopa powder, insulin liquid, and olanzapine powder for the treatment of Parkinson’s disease, Alzheimer’s disease and agitation in schizophrenia and bipolar disorder, respectively.
The major players operating in nasal drug delivery systems market are Merck & Co., GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Baxter International, Inc., Valeant Pharmaceuticals International, Inc., Becton, Dickinson and Company, and Novartis AG.
Click To Read More On: Nasal Drug Delivery Systems Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Global Parkinson’s Disease Treatment Market
Global Parkinson’s Disease Treatment Market is expected to reach USD 6.48 Billion by 2024 from USD 4.02 Billion in 2016 at CAGR of 6.15% .
Parkinson’s Disease is the combination of progressive, degenerative neurological motor disorder, primarily affecting the dopaminergic cells of the brain. Rigidity, tremor, bradykinesia and postural instability are some of the common symptoms of Parkinson’s Disease.
Global Parkinson’s Disease Treatment Market is segmented by drug class, patient care setting, distribution channel, and geography. Drug Class segment is sub-segmented as levodopa/carbidopa, dopamine receptor agonists, Mao-inhibitors and others. Distribution channel segment is classified as hospital pharmacies, retailer pharmacies, and online pharmacies. Hospital pharmacies segment is expected to dominate the market during the forecast period. A rising number of patient visits to the hospital due to the availability of diagnostic laboratories is expected to fuel the segment growth. Patient care setting segment is bifurcated as hospitals and clinics. The market on the basis of geography is segmented by North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
Increasing prevalence and rise in incidences of Parkinson’s disease across the developed countries are trending the overall Global Parkinson’s Disease Treatment Market. However, the availability of conventional treatment methods will restrain the market growth. APAC is expected to register the highest growth rate in Parkinson’s Disease Treatment Market during the forecast period followed by North America and Europe. The increasing number of generic drug manufacturers and rising aging population in this region will fuel the Parkinson’s Disease Treatment Market in the APAC region.
Key Highlights:
• Assessment of market definition along with the identification of key players and an analysis of their strategies to determine the competitive outlook of the market, opportunities, drivers, restraints, and challenges for this market during the forecast period
• Complete quantitative analysis of the industry from 2016 to 2024 to enable the stakeholders to capitalize on the prevailing market opportunities
• In-depth analysis of the industry on the basis of market segments, market dynamics, market size, competition & companies involved value chain
• Global Parkinson’s Disease Treatment Market analysis and comprehensive segmentation with respect to the drug class, patient care setting, distribution channel, and geography to assist in strategic business planning
• Global Parkinson’s Disease Treatment Market analysis and forecast for five major geographies North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and their key regions
Research Methodology:
The research methodology used in this report contains various secondary sources including Bloomberg, Hoovers, and Factiva. Experts from top manufacturing companies along with other stakeholders have been considered. This is done to validate and collect critical information for evaluating trends related to this market during the forecast period. Top-down and bottom-up approaches have been used to estimate the global and regional size of this market. Data triangulation techniques along with other comparative analysis are also used to calculate the exact size of the Global Parkinson’s Disease Treatment Market globally.
For More Information Visit@
https://www.maximizemarketresearch.com/market-report/global-parkinsons-disease-treatment-market/6655/
Key Players in the Global Parkinson’s Disease Treatment Market Are:
• GSK
• Novartis
• UCB
• F. Hoffmann-La Roche AG
• STADA Arzneimittel AG
• Acadia
• Wockhardt
• Sun Pharma
• Lundbeck
• Valeant Pharmaceuticals
• Abbvie
• Impax
• Boehringer Ingelheim
• Teva
• Merck
Key Target Audience:
• Research and Consulting Firms as well as Venture capitalists, private equity firms, and startup companies
• Academic institutions
• Parkinson’s disease treatment dealers and suppliers
• Parkinson’s disease treatment product manufacturers
• Parkinson’s disease associations
• Human identification service providers
• Contract research organizations (CROs)
• Government Bodies
Scope of the Report:
Research report categorizes the Global Parkinson’s Disease Treatment Market based on drug class, patient care setting, distribution channel, and geography (region wise). Market size by value is estimated and forecasted with the revenues of leading companies operating in the Global Parkinson’s Disease Treatment Market with key developments in companies and market trends.
Global Parkinson’s Disease Treatment Market, By Drug Class:
• Levodopa/carbidopa
• Dopamine Receptor Agonists
• MAO-Inhibitors
• COMT-inhibitors
• Anticholinergics
• Other Drugs
Global Parkinson’s Disease Treatment Market, By Distribution Channel:
• Hospital Pharmacies
• Retailer Pharmacies
• Online Pharmacies
Global Parkinson’s Disease Treatment Market, By Patient Care Setting:
• Hospitals
• Clinics
Global Parkinson’s Disease Treatment Market, By Geography:
• North America
• Europe
• Asia Pacific
• Middle East & Africa
• Latin America
Available Customization:
Maximize Market Research offers customization of report and scope of the report as per the specific requirement of our client.
This Report IsSubmitted By @Maximize Market Research Company
Customizationof the report:
MaximizeMarket Research provides free personalized of reports as per your demand. Thisreport can be personalized to meet your requirements. Get in touch with us andour sales team will guarantee provide you to get a report that suits yournecessities.
AboutMaximize Market Research:
MaximizeMarket Research provides B2B and B2C research on 20,000 high growth emergingopportunities & technologies as well as threats to the companies across theHealthcare, Pharmaceuticals, Electronics & Communications, Internet ofThings, Food and Beverages, Aerospace and Defense and other manufacturingsectors.
Contactinfo:
Name: Lumawant Godage
Organization: MAXIMIZEMARKET RESEARCH PVT. LTD.
Email: [email protected]
Address: Omkar Heights, Sinhagad Road, Manik Baug,Vadgaon Bk,Pune, Maharashtra 411051, India.
Contact: +919607195908
0 notes
Text
Levodopa Market: Business Planning Research, Reviews & Comparison of Alternatives 2026
Levodopa Market: Business Planning Research, Reviews & Comparison of Alternatives 2026
Levodopa or L-Dopa is a chemical building-block that converts into a dopamine in body. Dopamine is the chemical messenger released in brain. It mediates pleasure, cognition, and memory functions. Nearly all patients receive the dopamine precursor levodopa, which adequately control symptoms of Parkinson’s disease (PD) at early stage of the disease. Carbidopa is often included with…
View On WordPress
0 notes
Text
Lewy Body Dementia Treatment Centers An In-Depth Study of Top Companies
Global Lewy Body Dementia Treatment Market- A report by Fact.MR
Fact.MR, in its latest business intelligence study, depicts the nuts and bolts of the global lewy body dementia treatment centers. The lewy body dementia treatment market report presents detailed information regarding the drivers, restraints, opportunities and trends affecting market growth. Each segment along with its sub-segment is analyzed in terms of value and volume. Further, the keyword report elaborates the market behavior of each vendor operating in the lewy body dementia treatment market.
The lewy body dementia treatment market considers the following years to present the overall market growth:
History Year: 2013 - 2017
Base Year: 2013
Estimated Year: 2028
Forecast Year: 2018 – 2028
Key findings of the lewy body dementia treatment market study:
Regional breakdown of the keyword market based on predefined taxonomy.
Innovative manufacturing processes implemented by keyword vendors in detail.
Region-wise and country-wise fragmentation of the keyword market to grasp the revenue, and growth outlook in these areas.
Changing preferences among consumers across various regions and countries.
Factors (Positive and Negative) impacting the growth of the global keyword market.
On the basis of Drug Type, the lewy body dementia treatment market study consists of:
Cholinesterase Inhibitors
Antipsychotic Drugs
Carbidopa-Levodopa
Antidepressants
Benzodiazepine
Modafinil
On the basis of Distribution Channel, the lewy body dementia treatment market study incorporates:
Online Pharmacies
Drug Stores
Retail Pharmacies
Hospital Pharmacies
For a detailed industry outlook, Get the Report Sample at: https://www.factmr.com/connectus/sample?flag=S&rep_id=1154
On the basis of region, the lewy body dementia treatment market study contains:
North America (U.S., Canada)
Europe (U.K., Germany)
Latin America (Brazil, Mexico)
South Asia (Thailand, Indonesia)
Key players analyzed in the lewy body dementia treatment market study:
BioArctic AB
Eisai Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Jazz Pharmaceuticals, Inc.
Immungenetics AG
Noven Pharmaceuticals, Inc.
Eli Lilly and Company
Novartis AG
Pfizer Inc.
Bayer AG
Mylan NV
Sanofi AG
Teva Pharmaceutical Industries Limited
GlaxoSmithKline plc
Takeda Pharmaceutical Company Limited
Queries addressed in the lewy body dementia treatment market report:
How has the global lewy body dementia treatment market grown over the historic period of 2013-2017?
Why are the lewy body dementia treatment market players targeting region for increased product sales?
What patented technologies are the players utilizing in the global lewy body dementia treatment market?
Which regions are displaying the fastest growth in the lewy body dementia treatment market?
What are the underlying micro- macroeconomic factors affecting the global lewy body dementia treatment market?
Request for Report Methodology: https://www.factmr.com/connectus/sample?flag=RM&rep_id=1154
Why choose Fact.MR?
Reports published by Fact.MR are a result of the combination of our experts and digital technologies. We thrive to provide innovative business solutions to the clients as well as tailor the reports aligning with the clients’ requisites. Our analysts perform comprehensive research to offer ins and outs of the current market situation. Clients across various time zones tend to utilize our 24/7 service availability.
0 notes
Text
Parkinson’s Disease Drugs Market Outlook : Industry Share, Size, Growth And Analysis Report 2022
09 October 2018: Parkinson’s disease belongs to the group of conditions called motor system disorders. This disease is a result of loss of dopamine producing neurons in the brain. The four primary symptoms of Parkinson’s disease are tremors, rigidity, slowness of movement and postural instability. Although, there is no cure for Parkinson’s disease, several medications are used to suppress the symptoms of the disease.
As per RNCOS report “Global Parkinson’s Disease Drugs Market Outlook 2022”, the global Parkinson’s disease drugs market is anticipated to witness a moderate growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global Parkinson’s disease drugs market. The report provides insight about the major drivers, such as increasing awareness about Parkinson’s disease and its treatment options, research grants and funds, for the global Parkinson’s disease drugs market.
Request A Sample Copy of This Report at: https://www.radiantinsights.com/research/global-parkinsons-disease-drugs-market-outlook-2022/request-sample
Furthermore, few challenges, such as patent expiry and high cost of treatment, which are hindering the growth of the global Parkinson’s disease drugs market have also been mentioned in the report. In addition, the report also highlights various opportunities available for growth of the global Parkinson’s disease drugs market.
The global Parkinson’s disease drugs market has been segmented on the basis of type of therapy into levodopa therapy, dopamine therapy, MAO-B inhibitor therapy, COMT inhibitor therapy, and other types of therapies. Among all the types, levodopa therapy is the first and most potent treatment for the Parkinson’s disease. The benefits of the medication are witnessed soon after administration.
Browse Full Research Report with TOC on https://www.radiantinsights.com/research/global-parkinsons-disease-drugs-market-outlook-2022
Apart from these types of therapies, various pharmaceutical and biotech companies are also developing stem cell therapy for the treatment of Parkinson’s disease. Stem cell therapy is an evolving field which makes use of stem cells to treat or prevent a disease or condition, such as Parkinson’s disease. Even a minimal success from this procedure can mean significant improvement in quality of life for patients.
Numerous companies, such as SanBio Inc and International Stem Cell Corp, are carrying out clinical trials for stem cell therapies for the treatment of Parkinson’s disease. Hence, stem cell therapy presents great opportunities for the growth of global Parkinson’s disease drugs market in the coming years.
Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America accounted for the largest share in the global Parkinson’s disease drugs market. Moreover, the report also highlights various mergers and acquisitions taking place in the global Parkinson’s disease drugs industry. The drugs pipeline of Parkinson’s disease has also been mentioned in the report.
The last section of the report discusses about the prominent players in global Parkinson’s disease drugs market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios and product pipeline. The recent developments of every player have also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global Parkinson’s disease drugs market.
About Radiant Insights Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Media Contact: Michelle Thoras 201 Spear Street 1100, Suite 3036, San Francisco, CA 94105, United States Tel: 1-415-349-0054 Toll Free: 1-888-928-9744 Mail: [email protected]
#Parkinson’s Disease Drugs Market Forecast#Parkinson’s Disease Drugs Market Scope#Parkinson’s Disease Drugs Market Demand#Parkinson’s Disease Drugs Industry
0 notes
Text
Global Lewy Body Dementia Drugs Market Overview 2021: Global Demand Analysis & Opportunities Outlook 2026 Novartis, Pfizer, Bayer, GlaxoSmithKline,
The Global Lewy Body Dementia Drugs Market is expected to reach US$ 5.3billion by 2027, with a CAGR of 5.9%from 2020 to 2027
Lewy body dementia (LBD) is a type of progressive dementia that leads to a decline in thinking, reasoning and independent function because of abnormal microscopic deposits that damage brain cells over time. Causes and risks. Symptoms. Treatment. Diagnosis.
This report analyzes the factors affecting the Lewy Body Dementia Drugs in terms of supply and demand and further assesses the market dynamics affecting the market during the forecast period e.g. drivers, restraints, opportunities and future trends. The report also provides Porter's five forces analysis of global scenarios.
Key Players Mentioned: Novartis, Pfizer, Bayer, GlaxoSmithKline, Mylan, Sanofi, Johnson & Johnson, Teva Pharmaceuticals, Eli Lilly, Eisai, Takeda Pharmaceutical, Allergan, Bausch Health Companies, BioArctic, Sumitomo Dainippon Pharma, Jazz Pharmaceuticals, Hisamitsu Pharmaceutical
For Right Perspective & Competitive Insights, Request a Sample @:
https://www.imrmarketreports.com/request/18556
This report provides a thorough overview of the competitive landscape of global Lewy Body Dementia Drugs Market and a detailed business profile of notable players in the market. Using industry standard tools like Porter's five force analysis and SWOT analysis, analysts in the report measure threats and weaknesses in key companies. The market report covers all key parameters such as product innovation, market strategy for leading companies, market share, revenue generation, the latest research and development and market expert perspectives.
Product Segment Analysis: Modafinil, Benzodiazepine, Antidepressants, Cholinesterase Inhibitors, Antipsychotic Drugs, Carbidopa-Levodopa
Application Segment Analysis: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Regional Segment Analysis: USA, Europe, Japan, China, India, South East Asia
The Global Lewy Body Dementia Drugs Market Report was produced through extensive primary and secondary studies. The report also focuses on qualitative and quantitative assessments by analyzing data collected from industry analysts and market participants across key points in the industry's value chain, growth aspects, utilization and manufacturing capabilities.
Get Your Copy at a Discounted Rate!!! Limited Time Offer!!!:
https://www.imrmarketreports.com/discount/18556
This report analyzes the factors affecting the Lewy Body Dementia Drugs Market in terms of supply and demand and further assesses the market dynamics affecting the market during the forecast period e.g. drivers, restraints, opportunities and future trends. The report also provides Porter's five forces analysis of global scenarios.
The Report allows you to: - Formulate significant competitor information, analysis and insights to improve your R&D strategy. - Identify potentially strong product portfolios emerging players and create effective response strategies to gain a competitive edge. - Identify and understand important and diverse types of Lewy Body Dementia Drugs under development - Develop market entry and market expansion strategies - Identify the main players with the most promising pipeline to effectively plan mergers and acquisitions. - In-depth analysis of the product's current development phase, area, and expected release date.
Key Points covered in the Lewy Body Dementia Drugs Market Report Coverage: 1 Market share study of the top manufacturing players 2 Market share debts for the regional and country level segments 3 Premeditated references for the new competitors 4 Competitive landscaping planning the key common trends 5 Tactical endorsements in key business segments based on the market estimations 6 Market Trends (Constraints, Drivers, Opportunities, Threats, Challenges, recommendations and Investment Opportunities) 7 Company profiling with detailed strategies, financial and latest developments 8 Supply chain trends mapping the latest technological advancements
Get More Insights:
https://www.imrmarketreports.com/request/18556
About Us:
IMR Market Reports is a visionary market research company who is ready to assist their clients to grow their business by offering strategies through our market research reports for gaining success. We have a well experienced team, who work efficiently and provides complete excellent research data in a complete sync to provide overall coverage and accurate market insights on various industries.
Contact Us:
Aditya Patil
Business Development Executive
Office Address: Office No 15, Vrundavan Commercial Complex, DP Road, Kothrud, Pune, India - 411038
Contact No:
USA: +1 (773)-382-1047
APAC: +91-818-009-6367
0 notes
Text
Parkinson's Disease Drugs Market Methodology, Introductio, Manufacturing, Analysis and Forecasts 2022
Parkinson’s Disease Belongs to the group of conditions called motor system disorders. This disease is a result of loss of dopamine producing neurons in the brain. The four primary symptoms of Parkinson’s disease are tremors, rigidity, slowness of movement and postural instability. Although, there is no cure for Parkinson’s disease, several medications are used to suppress the symptoms of the disease.
As per RNCOS report “Global Parkinson’s Disease Drugs Market Outlook 2022”, the global Parkinson’s disease drugs market is anticipated to witness a moderate growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global Parkinson’s disease drugs market. The report provides insight about the major drivers, such as increasing awareness about Parkinson’s disease and its treatment options, research grants and funds, for the global Parkinson’s disease drugs market.
Furthermore, few challenges, such as patent expiry and high cost of treatment, which are hindering the growth of the global Parkinson’s disease drugs market have also been mentioned in the report. In addition, the report also highlights various opportunities available for growth of the global Parkinson’s disease drugs market.
Request A Sample copy of This Report @ http://www.hexareports.com/report/global-parkinsons-disease-drugs-market-outlook-2022/request-sample
The global Parkinson’s disease drugs market has been segmented on the basis of type of therapy into levodopa therapy, dopamine therapy, MAO-B inhibitor therapy, COMT inhibitor therapy, and other types of therapies. Among all the types, levodopa therapy is the first and most potent treatment for the Parkinson’s disease. The benefits of the medication are witnessed soon after administration.
Apart from these types of therapies, various pharmaceutical and biotech companies are also developing stem cell therapy for the treatment of Parkinson’s disease. Stem cell therapy is an evolving field which makes use of stem cells to treat or prevent a disease or condition, such as Parkinson’s disease. Even a minimal success from this procedure can mean significant improvement in quality of life for patients.
Numerous companies, such as SanBio Inc and International Stem Cell Corp, are carrying out clinical trials for stem cell therapies for the treatment of Parkinson’s disease. Hence, stem cell therapy presents great opportunities for the growth of global Parkinson’s disease drugs market in the coming years.
Browse Detail Report With TOC @ http://www.hexareports.com/report/global-parkinsons-disease-drugs-market-outlook-2022
Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America accounted for the largest share in the global Parkinson’s disease drugs market. Moreover, the report also highlights various mergers and acquisitions taking place in the global Parkinson’s disease drugs industry. The drugs pipeline of Parkinson’s disease has also been mentioned in the report.
The last section of the report discusses about the prominent players in global Parkinson’s disease drugs market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios and product pipeline. The recent developments of every player have also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global Parkinson’s disease drugs market.
Table Of Content
Analyst View
Research Methodology
Parkinson’s Disease: An Overview
Market Dynamics
Global Parkinson’s Disease Drugs Market Outlook 2022
Market Segmentation by Type of Therapy
Market Segmentation by Geography
Trends & Developments
Mergers & Acquisitions
For More Details Visits @ Hexa Reports
0 notes
Text
Levodopa Market - Size, Share, Outlook, and Opportunity Analysis 2018 – 2026
Levodopa or L-Dopa is a chemical building-block that converts into a dopamine in body. Dopamine is the chemical messenger released in brain. It mediates pleasure, cognition, and memory functions. Nearly all patients receive the dopamine precursor levodopa, which adequately control symptoms of Parkinson's disease (PD) at early stage of the disease. Carbidopa is often included with levodopa-containing drugs in order to boost its efficacy by slowing down the metabolism of dopamine.
Levodopa Market Driver Development of novel formulations and efficient drug delivery methods for levodopa are expected to drive growth of the levodopa market. For instance, a clinical study for gastric retentive Accordion Pill, an immediate drug release formulation by Intec Pharma Ltd., is ongoing in clinical phase III and is expected to complete in September 2018. Accordion Pill is a Carbidopa/Levodopa (AP-CD/LD) combinational oral drug delivery system, which is designed to improve the efficacy and safety of existing CD/LD drugs by utilizing an efficient gastric retention and specific release mechanism.
Request A Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/2247
Furthermore, advancement in diagnosis of Parkinson's disease (PD) progression is expected to boost growth of levodopa market. For instance, a clinical study conducted by Washington University School of Medicine, for measuring PD progression both by using Magnetic Resonance Imaging (MRI) and by controlled dose of levodopa for discovering suitable biomarker of PD is currently in clinical phase I and is expected to complete in February 2019. Levodopa Market Restraint Shortage of drug supply in the market due to delay in manufacturing and supply of levodopa is expected to hamper levodopa market growth. For instance, Merck Sharp & Dohme Ireland (Human Health) Ltd. in September 2018, anticipated stock shortage of some Sinemet (Carbidopa/ Levodopa) products in the Irish market in near future due to global manufacturing delays in production and demand for resupply of these products.
Levodopa Market – Regional Analysis On the basis of region, the global levodopa market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Europe region is expected to witness significant growth in levodopa market due to involvement of key players for marketing novel formulations in European region. For instance, Acorda Therapeutics, Inc., in March 2018, submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for INBRIJA, an investigational inhaled levodopa treatment for symptoms of OFF periods (OFF symptoms implies recurrence of symptoms such as rigidity, and tremors after long period of levodopa use) in people with PD taking a Carbidopa/Levodopa regimen.
Furthermore, in November 2015, Impax Laboratories, Inc. received European Commission (EC) marketing authorization for NUMIENT (Levodopa and Carbidopa), a modified-release oral capsule formulation for the symptomatic treatment of adult patients with Parkinson's disease in Europe region. Levodopa Market – Taxonomy By Application Parkinson’s Disease,Dopamine Responsive Dystonia By Drug Type Rytary,Duopa,Sinemet,Caramet,Others By Distribution Channels,Hospital Pharmacies,Retail Pharmacies,Online Pharmacies,By Region,North America,Europe,Asia Pacific,Latin America,Middle East,Africa Click To Read More On Levodopa Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us: Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email:[email protected]
0 notes
Link
Press Release: Pune, India- August , 2017 Global Parkinson’s Disease Drugs Market Outlook 2022 Description: Parkinson’s disease belongs to the group of con
0 notes